Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Feb 26;13(2):e13574.
doi: 10.7759/cureus.13574.

Intolerance to Multiple P2Y12 Inhibitors Following Percutaneous Coronary Intervention

Mina Shnoda  1 , Kinan Kassar  2 , Deanna L Huffman  1 , Vijaya Sanikommu  3 , Indu Poornima  2
Affiliations
Case Reports

Intolerance to Multiple P2Y12 Inhibitors Following Percutaneous Coronary Intervention

Mina Shnoda et al. Cureus. .

Abstract

Dual antiplatelet therapy (DAPT), defined as administration of a P2Y12 receptor inhibitor (clopidogrel, prasugrel, or ticagrelor) and aspirin, is recommended after percutaneous coronary intervention. We describe a case of a 50-year-old gentleman with intolerance to the three previously mentioned P2Y12 inhibitors following the placement of a drug-eluting stent to the left anterior descending artery. To our knowledge, based on a thorough review of the literature, this is the second case reporting a similar medical dilemma. We have discussed the multidisciplinary approach implemented to overcome this clinical challenge, which involved the use of clopidogrel with simultaneous administration of a six-day course of oral steroids.

Keywords: clopidogrel hypersensitivity; multiple drug intolerance; p2y12 inhibitors; percutaneous coronary intervention.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Rash predominantly affecting patient’s chest
See this image and copyright information in PMC

References

    1. Characterization of clopidogrel hypersensitivity reactions and management with oral steroids without clopidogrel discontinuation. Cheema AN, Mohammad A, Hong T, et al. J Am Coll Cardiol. 2011;58:1445–1454. - PubMed
    1. Allergic reactions to clopidogrel and cross-reactivity to other agents. Lokhandwala J, Best PJM, Henry Y, Berger PB. Curr Allergy Asthma Rep. 2011;11:52–57. - PubMed
    1. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) CAPRIE Steering Committee. Lancet. 1996;348:1329–1339. - PubMed
    1. Prasugrel-induced hypersensitivity skin reaction. Kim S-H, Park S-D, Baek Y-S, et al. Korean Circ J. 2014;44:355–357. - PMC - PubMed
    1. Rash with both clopidogrel and ticlopidine in two patients following percutaneous coronary intervention with drug-eluting stents. Makkar K, Wilensky RL, Julien MB, Herrmann HC, Spinler SA. Ann Pharmacother. 2006;40:1204–1207. - PubMed

Publication types

LinkOut - more resources